ZEAL News

News
all
press releases
OTR Therapeutics and Zealand Pharma enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases
OTR Therapeutics and Zealand Pharma enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases OTR Therapeutics and Zealand Pharma enter...
PR Newswire
OTR Therapeutics and Zealand Pharma enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases
OTR Therapeutics and Zealand Pharma enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases OTR Therapeutics and Zealand Pharma enter...
PR Newswire
More News
Investing.com -- Wells Fargo has initiated coverage of Zealand Pharma (NASDAQ:ZEAL) with an Overweight rating and a DKK 650 price target, seeing the Danish biotech as poised to become “a key obesity player” thanks to its differentiated pipeline targeting the rapidly expanding weight loss market.
investing.com
Investing.com - Shares of European drugmakers slipped on Wednesday after U.S. President Donald Trump said that tariffs of up to 200% on pharmaceutical imports could be coming "very soon."
investing.com
Investing.com -- Morgan Stanley upgraded its rating on Zealand Pharma (NASDAQ:ZEAL) shares to Overweight from Equal Weight, highlighting a “long-term obesity potential” unlocked by the company’s recent partnership with Roche (SIX:ROG).
investing.com
Investing.com -- Zealand Pharma shares surged more than 41% on Wednesday after announcing a $5.3 billion licensing deal with Roche for its GLP-1 obesity therapy petrelintide. 
investing.com
Investing.com -- Novo Nordisk (CSE:NOVOb) (NYSE:NVO) shares slumped Wednesday after Roche (SIX:ROG) struck a $5.3 billion deal to acquire rights to an obesity treatment from Denmark’s Zealand Pharma A/S (CSE:ZELA).
investing.com

Advertisement|Remove ads.